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Abstract
Psoriasis is an immune-mediated skin disease which affects 2–
4% of the worldwide population. Approximately 20–30% of
patients with psoriasis develop psoriatic arthritis (PsA), a fre-
quently destructive and disabling condition. As skin manifesta-
tions precede joint symptoms in nearly all patients with PsA,
identification of biomarkers for early prediction of joint dam-
age is an important clinical need. Because not all patients with
PsA respond to treatment in the same fashion, identification of
biomarkers capable of predicting therapeutic response is also
imperative. Here, we review existing literature and discuss cur-
rent investigations to identify potential biomarkers for PsA dis-
ease activity, with particular emphasis on microRNAs as novel
markers of interest. Serum (soluble) biomarkers, peripheral
osteoclast precursor as cellular biomarkers, and genetic loci
associated with skin and joint disease are also reviewed.
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Introduction
Advances in our understanding of immune-mediated inflam-
matory diseases have fueled the development of targeted
therapies that alter the course of disease progression, impart-
ing significant beneficial effects on prevention of disease-
associated morbidity. However, the pathophysiology of many
autoimmune skin and joint diseases remains an enigma. This
frequently results in significant morbidity and mortality,
whether from the condition itself or due to the treatment.
Psoriasis is a common immune-mediated skin disease,
affecting 2–4% of the worldwide population, and has been
associated with various comorbidities, including cardiovascu-
lar disease, metabolic syndrome, cancer, and depression (1,2).
Genetic, immunologic, and environmental factors are postu-
lated to contribute to disease phenotype. Although traditionally
considered a Th1-mediated disease, recent advances have
identified a role for Th17 cells in psoriasis (3).
Approximately 20–30% of patients with psoriasis develop
psoriatic arthritis (PsA); however, little is known about the
immunopathogenesis of these diseases and prognostic factors
that lead to their development (4). Skin lesions of psoriasis are
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generally observed 5–10 years prior to the development of
PsA, although joint disease may present first or may never
develop (5). PsA can be divided into five clinical subsets, as
first described by Moll and Wright in 1973: spondyloarthritis,
distal arthritis, oligoarthritis, symmetrical polyarthropathy
similar to rheumatoid arthritis (RA), and arthritis mutilans.
Patients may demonstrate transitions between these subsets
throughout the course of the disease. Early diagnosis and
intervention are key to preventing permanent joint deforma-
tion. However, no standardized method exists for early detec-
tion of PsA, and many patients with psoriasis also have
undiagnosed PsA (6). Furthermore, psoriasis and PsA have
been associated with various comorbidities, including cardio-
vascular disease, metabolic syndrome, cancer, and depression;
thus, interventions that beneficially impact disease may also
significantly affect morbidity and mortality (1,2).
Biomarkers, or measurable biological indicators of disease
activity, may be used to predict future disease, measure current
disease activity, or quantify therapeutic efficacy (7). For exam-
ple, in RA, rheumatoid factor and anticitrullinated protein anti-
bodies are used to diagnose and prognosticate disease. Ideally,
biomarkers should be easy to obtain, sensitive, specific, repro-
ducible, and prognostic. Broadly, they can be classified into
soluble biomarkers, cellular biomarkers, and genetic bio-
markers. Biomarkers in PsA have been identified as a relevant
research gap, and the development of cohort and longitudinal
studies have been proposed to address this need (8). Currently,
there are no validated biomarkers to predict the progression of
PsA or prognosticate response to available therapies. We review
ongoing investigations to identify potential target biomarkers
for PsA and to discuss future directions for exploration.
Soluble Biomarkers
Because of the ease of accessibility, circulating biomarkers
obtained from peripheral blood are optimal indicators of dis-
ease activity. In psoriasis, they are broadly categorized into
nonspecific inflammatory markers, indicators of metabolic
processes, and immunologic markers. Elevated levels of non-
specific inflammatory markers, including haptoglobin, C-
reactive protein (CRP), and P-selectin, and proinflammatory
cytokines, such as interleukin (IL)26, IL-8, IL-12, IFN-c, and
tumor necrosis factor alpha (TNF-a), have been identified in
serum of patients with psoriasis (9). In addition, circulating
Th1, Th17, and Th22 cells and increased expression of IL-23
receptor (IL-23R) in T cells have been reported (10,11). Serum
adiponectin, a cytokine that improves insulin resistance, is
decreased in patients with psoriasis, whereas serum lipocalin,
leptin, and resistin are increased (12–14). Adiponectin has also
been found to be strongly associated with PsA and TNF-a ther-
apy (12). These metabolic markers may provide clues to the
link between psoriasis, metabolic syndrome, and cardiovascu-
lar disease.
In PsA, no single validated screening test exists for the
detection of joint involvement; however, several studies have
identified potential soluble biomarkers relating to inflamma-
tion and cartilage or bone metabolism. Serum IL-6, a proin-
flammatory cytokine produced by lymphoid and other cells,
has been found in greater quantity in patients with PsA versus
skin disease alone, correlating with number of joints affected
(15). However, this cytokine may also be upregulated by other
inflammatory processes, and therefore, it is not a specific
screening tool. Rather, a designated panel of soluble bio-
markers may best differentiate patients with psoriatic joint
involvement from those with only cutaneous lesions. In a
Canadian cohort, Chandran et al. (16) identified osteoprote-
gerin, high-sensitivity CRP (hs-CRP), cartilage oligomeric
matrix protein (COMP), matrix metalloproteinase 3 (MMP-3),
and the ratio of C-propeptide of type II collagen (CPII) to colla-
gen fragment neoepitopes Col2-3/4 (C2C ratio) in patients with
PsA versus psoriasis alone. In another study, Ramonda et al.
(17) identified MMP-3, hs-CRP, and vascular endothelial
growth factor as potential screening tools for the detection of
PsA.
In addition to serving as screening tools for PsA, soluble
biomarkers may measure disease activity by correlating with
temporal changes in other clinical parameters such as radio-
graphic change and response to therapy. Of the markers listed
above, a reduction in MMP-3 was associated with response to
TNF-a inhibitor therapy, suggesting its potential role in meas-
uring disease activity (18). Candidate circulating markers of
bone remodeling which may correlate with radiographic
change include Dickkopf-1 (Dkk-1), COMP, bone alkaline phos-
phatase, and macrophage-colony stimulating factor (M-CSF;
ref. (19)). Higher concentrations of Dkk-1 and M-CSF were
seen in patients with PsA; however, their levels did not corre-
late with radiographic changes or number of affected joints.
Peripheral Blood-Derived Osteoclast
Precursors as Cellular Biomarkers
for PsA
Joint damage is carried out by synovial fibroblastoid cells that
degrade cartilage through the release of metalloproteinases
and osteoclasts (OCs), which directly resorb bone. OCs are
multinucleated cells that arise from osteoclast precursor (OCP)
or circulating CD141 monocytes through a differentiation pro-
cess referred to as osteoclastogenesis (20). Myeloid-derived
cells differentiate into OCs in the presence of M-CSF and
RANKL. RANK and CSF 1 receptor (CSF-1R/c-fms) are both
expressed on OCP cells which, on stimulation with RANKL and
M-CSF, develop into mature bone-resorbing cells (21). Activa-
tor protein (AP-1), a transcriptional regulator composed of
members of the Fos and Jun families, is also required for OC
differentiation and has been implicated in PsA (22). OCs can
be generated from RANKL-, RANK-, or TRAF6-deficient mice,
suggesting that RANKL–RANK-independent OC differentiation
pathways also exist (23).
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Of particular interest in regards to PsA was the finding of
an increased frequency of OCP in one-third of patients with
psoriasis without arthritis and in the majority of patients with
PsA (24,25). Intriguingly, monocytes circulating in the periph-
eral blood of patients with PsA were able to generate OCs in
vitro in the absence of exogenous stimulation, a property dis-
tinct from OCP in healthy controls. Importantly, the frequency
of OCP correlated with the extent of radiographic damage in a
cohort of patients with established PsA (24).
The IL-23/IL-17 axis plays a critical role in osteoclastogen-
esis via a number of direct and indirect effects that both posi-
tively and negatively modulate OC formation. IL-23-induced
Th17 cell differentiation results in RANKL secretion and thus
promotes osteoclastogenesis (26). IL-17 also acts on osteo-
blasts to secrete RANKL to further enhance bone resorption.
IL-17 further modulates the expression of the OC fusion pro-
tein, dendritic cell-specific transmembrane protein, a potential
biomarker for early prognosis of PsA (27).
To date, there have been several reports characterizing
the entity of OCPs, although whether there are specific mono-
cytoid populations committed to differentiating exclusively into
OCs remains to be elucidated (28). Chiu et al. (29) found that
patients with PsA have an elevated percentage of CD141CD161
proinflammatory monocytes in the peripheral blood. Based on
the observation of CD16 upregulation in cells cultured in OC-
promoting (M-CSF and RANKL) but not DC-promoting condi-
tions (GM-CSF and IL-4), they further found that OCs arise
from circulating CD161 monocytes in PsA, whereas OCs were
generated from the CD162 subset in healthy controls. Finally,
they showed a positive correlation between the level of CD16
cell surface expression and the extent of bone resorption.
These studies indicate that the major reservoir of OCP in PsA
is CD161 cells, a finding that may catalyze the development of
susceptibility biomarkers for arthritis in patients with psoriasis
and a treatment response marker in patients with PsA with
erosive arthritis. In considering all of these potential bio-
markers, it should be noted that the majority are associated
with ongoing disease activity/damage, which may be helpful in
the diagnosis of arthritis and monitoring response to therapy.
However, at this time, these biomarkers provide little insight
into the prediction of arthritis prior to its onset, which is
where the greatest potential impact on disease and future dis-
ability may be imparted.
Genetic Biomarkers for PsA
Genetic factors play a significant role in psoriasis, as initially
reported by the identification of psoriasis susceptibility-1
(PSORS1) in family studies and association with major histo-
compatibility complex (MHC) haplotypes in case–control stud-
ies (30,31). The HLA-Cw*0602 allele has been well established
as the PSORS1 risk variant associated with early development
of psoriasis with a family history of psoriatic disease in Cauca-
sians (32). Genome-wide association studies (GWAS) have led
to candidate gene identification in psoriatic disease (33).
Outside the MHC, novel genetic loci have been associated with
psoriasis and PsA; these include the single-nucleotide polymor-
phism (SNP) rs4795067 encoding NOS2, rs10782001 encoding
FBXL19, and rs12586317 encoding PSMA6-NFKBIA (34). In
particular, the SNP rs10782001, which encodes the FBXL19
gene and activates NF-jB, is more strongly associated with
psoriatic joint disease than cutaneous psoriasis. The SNPs
rs20541 and rs1800925, both encoding IL-13, have been asso-
ciated with increased susceptibility to PsA in Caucasian
patients (35), whereas rs1800629 has been reported in cases
of early-onset psoriasis and joint erosions in PsA (36). Finally,
a locus on chromosome 4q27 expressing the IL-2 and IL-21
genes was found to be linked with PsA and other autoimmune
diseases, including type 1 diabetes mellitus, RA, Grave’s dis-
ease, and celiac disease (37).
In addition to determining genetic risk, SNPs have been
linked with therapeutic efficacy and may serve as markers to
predict treatment response. Polymorphisms in the TNF, TNF
receptor superfamily 1B (TNFR1B), and TNF alpha-induced
protein 2 gene (TNFAIP3) have been associated with response
to anti-TNF therapy (38,39). The SNP in the promoter of the
TNF gene at position 857T was found to be a risk factor for
PsA independent of the PSORS1 allele (36). Carriers of the
minor allele of TNF-308 polymorphism have also been
reported to experience an aggressive course of PsA (40). SNPs
mapping to the IL-23R and IL-12b gene confer susceptibility to
both cutaneous psoriasis and PsA, which supports the ration-
ale for treatment with ustekinumab, a monoclonal antibody
against IL-12 and IL-23, in these conditions (41).
Genetic biomarkers use SNPs within GWAS to identify
genetic susceptibility. However, the predictive potential for
individual genes in psoriatic disease is minimal, and weighted
genetic risk scores (wGRS) based on known psoriasis loci cur-
rently have limited efficacy as biomarkers (42). Chen et al. (43)
attempted to improve predictive ability by combining 10 psori-
asis risk loci into a simple risk alleles count (cGRS) or wGRS.
The wGRS was able to capture more risk than individual SNPs
and was linked to early disease onset and family history of
psoriatic disease. Despite these findings, analysis of multiple
genetic loci only accounted for 15% of psoriasis heritability.
Despite the identification of potential genetic markers in
PsA, the inability to accurately differentiate skin versus joint
disease, the low odds ratios for these target genes, and the rel-
atively modest risks associated with these loci, limit their cur-
rent utility.
MicroRNA Biomarkers
MicroRNAs (miRNAs) are a class of small noncoding RNAs that
negatively regulate the expression of protein-coding genes and
degrade target mRNAs. Emerging evidence suggests that
miRNA-mediated regulation represents a fundamental layer of
epigenetic control of diverse sets of physiological processes
and disease development. Studies from our laboratory and
others have reported the critical involvement of miRNAs in
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immune cell development and function. As miRNAs are
expressed in a tissue-specific manner and are altered in rela-
tion to disease, these noncoding RNAs represent ideal candi-
dates for biomarker discovery. One study evaluated the global
miRNA expression profiles of peripheral blood mononuclear
cells in patients with recent onset of PsA. A comparison of
miRNA profiles between PsA and healthy controls identified 16
miRNAs as differentially expressed, including the upregulation
of inflammatory linked miRNAs, miR-21, miR-34a, miR-125a-
3p, and miR-125a-5p. Recent studies from our laboratory and
others have demonstrated that serum contains stable miRNAs
derived from immune cells and various tissues, establishing
their potential value as biomarkers for changes in physiologic
and pathologic conditions (44–46). In fact, the use of circulat-
ing miRNA biomarkers has become an area of great interest;
identification of biomarkers for a wide number of diseases and
conditions has been reported to date (45). The ability to readily
detect changes in blood-based miRNAs is an attractive bio-
marker methodology, most notably due to the noninvasive
nature of blood collection and relative ease of high-throughput
detection systems for processing and analyzing miRNA con-
tent. Additionally, circulating miRNAs show remarkable stabil-
ity and demonstrate consistent expression profiles among indi-
viduals. As a result, serum miRNA biomarkers have been
reported in cancer, inflammation, and cardiovascular disease.
Several studies investigating the circulating miRNA profiles of
patients with psoriatic disease have found significant changes
in the expression of several miRNAs when compared with
healthy controls. Candidate biomarkers for psoriasis included
the upregulated expression of miR-33, miR-369-3p, miR-1266,
and miR-128 (47) and the downregulation of let-7d, miR-142-
3p, and miR-181a (47). Despite these reports, not much is
known regarding miRNA expression in patients with PsA, and
there has been no investigation into the alterations of miRNA
expression in the circulation of patients with PsA. However, it
has been suggested that serum miRNAs may provide a source
of candidate biomarkers for PsA (7).
Perspective
Recent advances in targeted biological therapy have allowed a
cohort of patients to experience remission from psoriasis and
PsA. Anti-TNF therapy, IL-12/23-targeted therapy, and IL-17A
blockade have demonstrated efficacy in previously resistant
disease (48). However, a minority of patients experience severe
side effects or remain resistant to treatment. In addition to
measuring disease activity, biomarkers may be able to direct
therapy and monitor for development of adverse reactions to
specific treatment modalities. Regrettably, to date, no PsA-
specific biomarker studied has shown clinical relevance, and
no large-scale studies have been conducted to determine
numeric thresholds for significance.
The Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis, known as GRAPPA, is an international con-
sortium of dermatologists and rheumatologists who have made
biomarker development a primary goal for psoriatic disease
(49). GRAPPA will be essential to the discovery and validation
of new biomarkers through collaborative efforts at patient
recruitment, funding, protocol development, study implemen-
tation, and data analysis (50). Through investigator-led trials,
such as the PsA BioDam study, the goal is to identify sensitive
and specific markers of joint disease in PsA. Biomarkers could
provide an objective, measurable method of diagnosis, in con-
junction with subjective, patient-reported screening question-
naires. In addition to identifying undiagnosed cases of PsA
among patients with psoriasis, a goal will be to detect bio-
markers that predict future development of PsA. Other poten-
tial avenues for future research include use of flow cytometry,
bioinformatics and proteomics using high-resolution mass
spectrometry, and molecular signaling. Recent advances in
proteomic technology are especially promising and may be
applied toward development of a validated biomarker panel,
which incorporates various methodologies for diagnostic, and
eventually prognostic, clinical value (51).
Biomarker development is a long and arduous process,
involving discovery, validation, and finally, clinical adoption.
Only a minority of candidate biomarkers are eventually used
in the clinical setting due to failure to validate, technical diffi-
culty, inaccessibility, or expense. Despite these obstacles, we
are hopeful that our goals of identifying a biologic basis for
treatment, recognizing prognostic markers for disease devel-
opment and treatment response, and developing targeted
therapies for disease management will be achieved.
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